Former Pfizer Senior Vice President Named CEO of Berlin Pharmaceutical Industry in a Partnership to Diversify and Expand Company Business in Asia

BANGKOK, July 14 /PRNewswire/ — Berlin Pharmaceutical Industry Co., Ltd., Thailand’s leading manufacturer and marketer of generic pharmaceuticals, named Amal Naj, a former Senior Vice President of New York-based Pfizer Inc., Chief Executive Officer and a member of the Board.

In addition, Berlin announced that it will partner with a newly established U.S.-based company, Paradigm Pharma, headed by Mr. Naj, to expand and diversify business in Thailand and key markets in Asia.

Mr. Naj is no stranger to Asia. Prior to his last position at Pfizer in New York, he was Country Manager of Pfizer Thailand and Indochina, a post he assumed in 2000. He is credited with restructuring and turning around Pfizer’s Thailand and Indochina operations and rapidly growing the business to its No. 1 position during his tenure. He joined Pfizer in 1997 after a long career as a journalist on the staff of the Wall Street Journal, where he covered steel, autos, and science and technology.

“We are very pleased to have Amal join us and lead Berlin into the next phase of the company’s growth,” said Dr. Termchai Chainuvati, Chairman. “He brings a wealth of experience, expertise, and knowledge of the region to help the company achieve its long term objectives,” he said. “Berlin is, and has been, a very successful company, and to continue to grow we must adopt new thinking and new strategies in a changing healthcare environment.”

Mr. Naj said, “Berlin is one of the most respected pharmaceutical companies in Thailand and stands in very high regard with the medical community. I am proud to be part of such a company.”

“It is also a great opportunity for me to partner with Berlin at a time the healthcare landscape is going through a massive change in Asia and rest of the world,” said Mr. Naj. “Governments are pushing to lower healthcare costs, and patients are demanding greater access to medicine and better care overall. At the same time, a vast number of drugs in wide ranging therapies—for treating infections, pain, diseases of the heart, and neurological disorders, among others—are losing their patents and becoming available to be manufactured by any company,” said Mr. Naj.

“It is truly a golden era for the patient in terms of being able to access medicines at affordable prices,” said Mr. Naj, “and it has created new opportunities for companies such as Berlin with a long record for high quality and low cost manufacturing.”

“We are witnessing a very interesting development in the pharmaceutical industry that favors strong generics companies. For the first time, large research-based pharmaceutical companies are entering the generics business in Asia and other emerging markets because their R&D investments haven’t produced many new innovative products. In a previously unthinkable trend, they are even copying each others’ patent-expired products to bolster their dwindling revenue base back home. In coming years, the once pricy medicines will take on the aura of commodity, manufactured in low-cost locations in the very backyards of local companies where they will be competing.”

“This trend is giving generics, especially local generics, the legitimacy—the perception of quality—they have lacked in the past,” said Mr. Naj. “But the commoditization of a vast number of these pharmaceutical products also means that competing on quality and cost alone will not be enough for any company small or large to succeed in the future. A successful company with staying power will have to offer the patient something more,” he said.

“Berlin was founded 78 years ago by a visionary, a doctor who often paid bus fare to the patient so that the patient could come back to complete the treatment. That is a very good foundation on which to build in the emerging healthcare environment”

Berlin manufactures and markets products mainly for treating cardiovascular (CV), metabolic, gastrointestinal (GI) diseases and ailments, and it is a market leader in many of these products. It employs 550 people.

Swiss stocks – Factors to watch on July 13

July 13 (Reuters) – Swiss stocks are seen opening a bit firmer on Tuesday, in line with other markets across Europe as confidence rises in the wake of forecast-beating figures from U.S. group Alcoa (AA.N).

The Swiss blue-chip index SMI .SSMI was indicated to open 2 points higher at 6,231 points, premarket data provided by bank Clariden Leu showed. CLPRE

The following are some of the main factors expected to affect Swiss stocks on Tuesday:

NESTLE (NESN.VX)

Luxury cosmetics group L’Oreal, in which Nestle owns a 30 percent stake, posted higher revenue in the second quarter helped by emerging markets and positive currency effects, confirming a recovery in consumer spending that started earlier this year.

For related news, click on [NESN.VX]

UBS (UBSN.VX)

UBS, battling hard to keep its star U.S. brokers in place after a tax evasion scandal, says it has turned the tide of defections.

For related news, click on [UBSN.VX]

NOVARTIS (NOVN.VX)

The American Society of Clinical Oncology issued new guidelines on Monday for the use of hormone-based breast cancer drugs called aromatase inhibitors.

Aromatase inhibitors include anastrozole, made by AstraZeneca (AZN.L) under the brand name Arimidex, exemestane, made by Pfizer Inc (PFE.N), under the brand name Aromasin and Novartis’s Femara or letrozole.

For related news, click on [NOVN.VX]

ECONOMY [M-CH]

* Swiss producer and import price data are due at 0715 GMT.ECONCH

COMPANY STATEMENTS [CNR-CH]

* Partners Group’s (PGHN.S) client demand results in inflows of 3.0 billion Sfr (EUR 2.1 billion) during the first half of 2010.

Partners Group is increasing its guidance to EUR 4 billion in assets raised for the full year 2010, which translates into 5.0-5.5 billion Sfr. [PGHN.S]

* Addex Pharmaceuticals Ltd. (ADXN.S) announced today that its preclinical drug candidate ADX71943 was effective in a model of osteoarthritis pain.[ADXN.S]

* Human Genome Sciences, Inc. and Lonza (LONN.VX) today announced an agreement for the future commercial supply of BENLYSTA, which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE).

* Nobel Biocare (NOBN.VX) received notification that UBS had a change to the composition of its group per 6 July 2010 and held 4.11 percent of the registered share capital of Nobel Biocare at that time.[NOBN.VX]

* Roche (ROG.VX) obtains co-exclusive license to develop PCR assays detecting mutations in the PI3K oncogene. [ROG.VX]

* ALTIN (ALTN.S) announces portfolio holdings as at 1st July 2010. [ALTN.S]

EQUITY RESEARCH [CH-RCH]

* Citigroup lowers ABB (ABBN.VX) price target to 25 Sfr from 26.30 Sfr

* JP Morgan raises SGS (SGSN.VX) price target to 1,524 Sfr from 1,507 Sfr

* BOFA Merrill raises SGS price target to 1,650 Sfr from 1,500 Sfr

* Goldman Sachs raises Nestle (NESN.VX) price target to 61.80 Sfr from 56.30 Sfr

* Goldman Sachs raises Aryzta (ARYN.S) price target to 38.90 Sfr from 37 Sfr

FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:

.EX.S for all Swiss stocks

.EXSMI.S for blue chips

.EXNSMI.S for other stocks

After reading this article, people also read:

* Lawsuits may reveal more Avandia dataJul 13, 2010
* US STOCKS-Futures higher after strong start to earnings seasonJul 13, 2010
* UPDATE 1-US cancer group endorses newer breast cancer drugsJul 12, 2010
* When It Comes to Rescission, DarrasLaw Says if We Can’t Get Rid of It, Let’s Prevent ItJul 13, 2010
* Addex Pharmaceuticals: Addex drug candidate effective in osteoarthritis pain modelJul 13, 2010

UPDATE 1-Sawai: to mull capital tie-up with bigger drugmaker

June 29 (Reuters) – Sawai Pharmaceutical (4555.T), Japan’s No.1 generic drug maker, said it will need to consider a capital tie-up with a bigger drugmaker in the future as it will need a larger budget for product development.

Stocks | Healthcare

“Our sales are strong now, but when it comes to several years from now, we will have to think about that,” Hiroyuki Sawai, Sawai Pharmaceutical’s chairman, told a news conference on Tuesday.

Sawai is faced with intensifying competition, especially from new foreign entrants to Japan’s generic drug market.

U.S. firm Pfizer Inc (PFE.N), the world’s biggest drugmaker, plans to enter Japan’s generic market, while France’s Sanofi Aventis (SASY.PA) is teaming up with Japan’s Nichi-iko Pharmaceutical (4541.OS) in the Japanese generic drug business.

Israel’s Teva Pharmaceutical (TEVA.TA), the world’s No.1 generic drug maker, began marketing in Japan earlier this year through a joint venture, targeting a 10 percent share of the Japanese generic drug market, which it expects to grow to 1 trillion yen ($11 billion) by 2015. (Reporting by Yumiko Nishitani)

Adolor Corporation to Present at the Ninth Annual Needham Healthcare Conference

EXTON, Pa.–(Business Wire)–
Adolor Corporation (NasdaqGM: ADLR) today announced that management will present
at the Ninth Annual Needham Healthcare Conference on Wednesday, June 9, 2010 at
11:20 A.M. Eastern Daylight Time. The conference is being held at The New York
Palace Hotel, New York City, New York.

Adolor`s presentation will be webcast live on the investor relations section of
the Company`s website and will be archived for one week following the broadcast.
To access the webcast, log onto the Company`s website at www.adolor.com and
click on “Investor Insights,” then “Webcast.” Click on the link and follow the
prompts for registration and access.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery,
development and commercialization of novel prescription pain management
products.

Adolor`s first approved product in the United States is ENTEREG (alvimopan),
which is indicated to accelerate the time to upper and lower gastrointestinal
recovery following partial large or small bowel resection surgery with primary
anastomosis. ENTEREG is available for short-term use in hospitals registered
under the E.A.S.E. Program. For more information on ENTEREG, including its full
prescribing information, visit www.ENTEREG.com. In collaboration with
GlaxoSmithKline (GSK), the Company launched ENTEREG in mid-2008.

The Company`s research and development pipeline includes: two novel delta opioid
receptor agonists, currently in mid-stage clinical development in collaboration
with Pfizer Inc. for chronic pain; two opioid receptor antagonists, ADL7445 and
ADL5945, entering development for chronic opioid bowel dysfunction (OBD); and
several opioid and non-opioid discovery programs.

For more information, visit www.adolor.com.

Adolor Corporation
Lizanne Wentz
484-595-1500

Copyright Business Wire 2010

Americans prefer drugs for depression, survey finds

June 1 (Reuters) – Americans prefer drugs to talk therapy for depression, with nearly 80 percent taking a pill for the condition, Consumer Reports said on Tuesday.

Stocks | Global Markets | Healthcare

The most popular class of drugs remain the so-called SSRIs such as Prozac, the group found. People found newer, pricier antidepressants less desirable because of side-effects.

Patients benefited just as much from therapy — almost any kind of therapy, the consumer group found in its survey of 1,500 readers.

Those surveyed said they improved just as much after seven or more sessions of talk therapy as if they took drugs and it did not matter if the therapist was a psychiatrist, psychologist or social worker.

Nearly 80 percent of people who had been diagnosed with depression or anxiety were prescribed antidepressants.

Patients were happiest with the selective serotonin reuptake inhibitors or SSRIs, a class that includes Eli Lilly and Co’s (LLY.N) Prozac or its generic equivalent fluoxetine;, Pfizer Inc’s (PFE.N) Zoloft or sertraline, and Celexa or citalopram and Lexapro o escitalopram from Forest Laboratories Inc (FRX.N).

People complained of more side-effects from serotonin-norepinephrine reuptake inhibitors or SNRIs, a newer, often more expensive class of antidepressants, the survey found.

These include venlafaxine, made by Pfizer-owned (PFE.N) Wyeth under the Effexor brand name and Lilly’s duloxetine, sold as Cymbalta.

The survey found a range of side-effects, but the most common one — loss of sexual interest or ability — was less common than in past surveys, the consumer group said.

U.S. will allow pilots to take antidepressants

(Reuters) – Pilots will soon be allowed to fly if they are taking antidepressant medications under new a U.S. government policy that takes effect Monday.

U.S. | Health

The Federal Aviation Administration said on Friday it was lifting a ban on antidepressants for pilots with mild to moderate depression. To be cleared to fly, pilots who take the drugs must pass screening tests to show they have been successfully treated for at least a year.

Officials said they believed the ban had caused pilots to forego treatment or hide the fact they were taking medication to treat depression. The FAA is offering a six-month grace period for pilots to come forward without penalty if they are currently suffering from depression or are under treatment.

“We need to change the culture and remove the stigma associated with depression. Pilots should be able to get the medical treatment they need so they can safely perform their duties,” FAA Administrator Randy Babbitt said.

Officials said they did not know how many pilots would be affected but noted that about 10 percent of the population suffers from depression.

Pilots who take antidepressants will be monitored for the length of their careers, the FAA said.

The policy applies to four antidepressants — Eli Lilly and Co’s Prozac, Pfizer Inc’s Zoloft, and Celexa and Lexapro from Forest Laboratories Inc.

Dr. Fred Tilton, the FAA’s federal air surgeon, said other medications may be allowed if pilots are being effectively treated with them.

Tilton said antidepressants were originally banned because older medications carried risks such as sedation that were considered unacceptable in the cockpit. Newer medications have side effects that can be manageable, he said.

(Reporting by Lisa Richwine; Editing by Steve Orlofsky))

U.S. will allow pilots to take antidepressants

(Reuters) – Pilots will soon be allowed to fly if they are taking antidepressant medications under new a U.S. government policy that takes effect Monday.

U.S. | Health

The Federal Aviation Administration said on Friday it was lifting a ban on antidepressants for pilots with mild to moderate depression. To be cleared to fly, pilots who take the drugs must pass screening tests to show they have been successfully treated for at least a year.

Officials said they believed the ban had caused pilots to forego treatment or hide the fact they were taking medication to treat depression. The FAA is offering a six-month grace period for pilots to come forward without penalty if they are currently suffering from depression or are under treatment.

“We need to change the culture and remove the stigma associated with depression. Pilots should be able to get the medical treatment they need so they can safely perform their duties,” FAA Administrator Randy Babbitt said.

Officials said they did not know how many pilots would be affected but noted that about 10 percent of the population suffers from depression.

Pilots who take antidepressants will be monitored for the length of their careers, the FAA said.

The policy applies to four antidepressants — Eli Lilly and Co’s Prozac, Pfizer Inc’s Zoloft, and Celexa and Lexapro from Forest Laboratories Inc.

Dr. Fred Tilton, the FAA’s federal air surgeon, said other medications may be allowed if pilots are being effectively treated with them.

Tilton said antidepressants were originally banned because older medications carried risks such as sedation that were considered unacceptable in the cockpit. Newer medications have side effects that can be manageable, he said.

(Reporting by Lisa Richwine; Editing by Steve Orlofsky))

Pfizer to outline Ratiopharm offer: sources

YORK/FRANKFURT (Reuters) – Pfizer Inc is set to make a near $4 billion offer for German generic drug maker Ratiopharm GmbH this week, competing with bids from Teva Pharmaceutical Industries Ltd and Actavis, several sources familiar with the situation said.

Deals

Pfizer, the world’s largest drugmaker, had previously cooled on Ratiopharm, however it was asked to rejoin the auction and present its bid to Ratiopharm’s board and management, two sources said.

Pfizer was expected to “be competitive” with a rival offer from Iceland’s Actavis, one source said, adding Pfizer could still walk away without submitting a binding offer.

The auction could linger several more weeks, with a decision unlikely before the end of the month, a second source said.

Several sources told Reuters in February that Teva and Iceland’s Actavis would be bidding for Ratiopharm. One source said at the time that the offer from Actavis was the highest, at close to 3 billion euros ($4.1 billion).

That would make the deal the biggest generics takeover since Teva’s $7.5 billion purchase of U.S. rival Barr, announced in July 2008.

Industrial heir Ludwig Merckle put Ratiopharm on the block as part of concessions made to creditors by his father Adolf Merckle, who committed suicide in January 2009 after ceding control of his business empire to lenders during the financial crisis.

Pfizer and Ratiopharm declined to comment.

Shares in Pfizer were down 0.85 percent and Teva shares were up 0.61 percent at 1157 GMT.

Pfizer is joining drug majors such as Sanofi-Aventis and Novartis who have coupled their traditional research-based drugs businesses with generics arms to turn the loss of patent exclusivity — at least in part — to their advantage.

Drugs representing annual sales of $95 billion are facing generic competition in the years 2009 to 2013.

The U.S. drugmaker has struck a string of collaboration deals and acquisitions to bolster its range of generics, particularly injectable drugs.

An alliance with India’s Strides Arcolab Ltd in January marked the latest step.

A tie-up with Ratiopharm could help Pfizer reduce costs at its generic pills business, analysts at Credit Suisse said.

Pfizer derives more than $10 billion in sales from off-patent drugs at its so-called “established products” unit — to a large part from its own medicines that have lost exclusivity.

(Reporting by Jessica Hall and Ritsuko Ando in New York, Deena Beasley in Los Angeles, Ludwig Burger in Frankfurt; Editing by Steve Orlofsky, Phil Berlowitz and Sharon Lindores)

China drug scams challenge pharmaceutical firms

BEIJING/HONG KONG (Reuters) – When Pang Jianli walked into a Beijing pharmacy to buy medicine for his flu-stricken son, he was greeted by an overwhelming display of boxes and bottles emblazoned with promises of miraculous cures.

“Unlike shopping in supermarkets, where I buy the brands I know and I know the brands I buy, buying drugs is different; the brands you know may not be what they claim to be,” said the 38-year-old father.

China’s poorly regulated medical market has spawned a new ‘Wild West’ for untested drugs offered by fly-by-night firms. The medical ‘free-for-all’ is reminiscent of the era of ‘snake-oil salesmen’ over a century ago in the United States.

From impotency treatments, to drugs that prevent hair loss, to medicines that cure chronic diseases, Chinese consumers are bombarded by adverts for a vast array of treatments making false or inflated promises.

Analysts say the murky business practices and misleading claims may actually help the prospects of foreign drug companies scrambling for a piece of the $110 billion medications market in China.

“Nowadays, Chinese people don’t trust Chinese medications. They trust Western brands more as they have a better reputation,” said Huang Jianshi, Assistant President of the Chinese Academy of Medical Sciences and Peking Union Medical College.

Foreign drug companies such as GlaxoSmithKline Plc and Pfizer Inc usually work directly with hospitals and doctors and rarely advertise, explained Du Jinsong, a pharmaceutical analyst with Credit Suisse in Hong Kong.

“Fake drug adverts have limited impact on foreign brands as foreign companies sell and market their products in a different way,” he said.

Treatments being aggressively touted don’t just promise to cure baldness or erase wrinkles, some also claim to cure chronic conditions such as hepatitis B, a disease that sometimes results in the need for a liver transplant, said Ewan So, president of the Society of Hospital Pharmacists of Hong Kong.

“If there was such a magic drug, we would have used it by now,” he said. “A liver transplant costs between HK$500,000 to HK$600,000. Why go to all that trouble?”

China’s State Food and Drug Administration (SFDA) counted 329,613 cases of the distribution of unlicensed drugs and medical products in 2007 and collected 746.17 million yuan (or $109 million) in fines.

But the fines have done little to deter the sale of untested drugs in a country where regulation is lacking and enforcement is lax. Analysts said it was hard to measure to what degree public mistrust of adverts have affected drug sales, which grew 26 percent to 752 billion yuan ($110 billion) last year in China.

“Like any other social issues in China, we now have adequate policy out there. The most crucial thing is how to effectively enforce the law,” said Xu Jun, a pharmaceutical analyst at Orient Securities in Shanghai.

GOVERNMENT IMPOTENCE

In an effort to clean up the industry, Beijing has issued a stream of curbs on advertising of medical products and services.

The latest rule, issued in February, banned actors from playing medical experts in advertisements for drugs after a group of Internet vigilantes exposed several fake experts.

Like many regulations in China, the rules have not been strictly enforced.

“There are still these TV adverts that go on for half an hour with people saying how they are completely cured after taking a certain drug or injection,” said activist Qing Song, a hepatitis B carrier. “But these are completely wrong.”

One Chinese company promoted its anti-impotence drug by pretending that soccer star David Beckham endorsed the product even though his name and image were used without his consent.

In the advert, which featured footage of Beckham playing football, a voice speaking Mandarin, purporting to be that of the English soccer player, extolled the virtues of the drug.

“Want to know how I can keep being strong and running on the field?” said the voice-over. “USA Selikon capsules give me a big help. It is also the secret weapon with which I satisfy Victoria,” it said, referring to Beckham’s celebrity wife.

Chinese law makes it difficult for international celebrities such as Beckham to sue firms that use their likeness without their consent.

To illustrate the extent of the touting of fake drugs, one leading Chinese search engine lost 2.1 percent of its online marketing ad revenue when the government issued one of its rules limiting advertising unlicensed drugs.

Still, despite bans, unlicensed and untested medical products are heavily promoted on the Internet, TV and billboards, as well as in newspapers and magazines across China.

Another problem is drug piracy. Sometimes fake drugs are packaged and sold to look like the medications of reputable firms.

In one case in January, the government ordered doctors to stop prescribing a well-known diabetes drug after a fake batch of the medicine was linked to the deaths of two patients in the far western region of Xinjiang.

With many Chinese lacking comprehensive medical coverage and opting to self-treat rather than visit doctors, experts say that tighter regulation and better enforcement are crucial to weed out disreputable firms. At risk is the health of tens of millions of people that purchase these medications across China.

“Unlike tainted food which we can avoid, people have to take pills even after hearing so much negative news about drug quality,” complained Pang as he exited a drug store.

(Additional report by Cheong Kah Shin; Editing by Doug Young and Megan Goldin)

RPT-FEATURE-China drug scams challenge pharmaceutical firms

By Michael Wei and Tan Ee Lyn

BEIJING/HONG KONG, April 20 (Reuters) – When Pang Jianli walked into a Beijing pharmacy to buy medicine for his flu-stricken son, he was greeted by an overwhelming display of boxes and bottles emblazoned with promises of miraculous cures.

“Unlike shopping in supermarkets, where I buy the brands I know and I know the brands I buy, buying drugs is different; the brands you know may not be what they claim to be,” said the 38-year-old father.

China’s poorly regulated medical market has spawned a new ‘Wild West’ for untested drugs offered by fly-by-night firms. The medical ‘free-for-all’ is reminiscent of the era of ‘snake-oil salesmen’ over a century ago in the United States.

From impotency treatments, to drugs that prevent hair loss, to medicines that cure chronic diseases, Chinese consumers are bombarded by adverts for a vast array of treatments making false or inflated promises.

Analysts say the murky business practices and misleading claims may actually help the prospects of foreign drug companies scrambling for a piece of the $110 billion medications market in China.

“Nowadays, Chinese people don’t trust Chinese medications. They trust Western brands more as they have a better reputation,” said Huang Jianshi, Assistant President of the Chinese Academy of Medical Sciences and Peking Union Medical College.

Foreign drug companies such as GlaxoSmithKline Plc (GSK.L) and Pfizer Inc (PFE.N) usually work directly with hospitals and doctors and rarely advertise, explained Du Jinsong, a pharmaceutical analyst with Credit Suisse in Hong Kong.

“Fake drug adverts have limited impact on foreign brands as foreign companies sell and market their products in a different way,” he said.

Treatments being aggressively touted don’t just promise to cure baldness or erase wrinkles, some also claim to cure chronic conditions such as hepatitis B, a disease that sometimes results in the need for a liver transplant, said Ewan So, president of the Society of Hospital Pharmacists of Hong Kong.

“If there was such a magic drug, we would have used it by now,” he said. “A liver transplant costs between HK$500,000 to HK$600,000. Why go to all that trouble?”

China’s State Food and Drug Administration (SFDA) counted 329,613 cases of the distribution of unlicensed drugs and medical products in 2007 and collected 746.17 million yuan (or $109 million) in fines.

But the fines have done little to deter the sale of untested drugs in a country where regulation is lacking and enforcement is lax. Analysts said it was hard to measure to what degree public mistrust of adverts have affected drug sales, which grew 26 percent to 752 billion yuan ($110 billion) last year in China.

“Like any other social issues in China, we now have adequate policy out there. The most crucial thing is how to effectively enforce the law,” said Xu Jun, a pharmaceutical analyst at Orient Securities in Shanghai.

GOVERNMENT IMPOTENCE

In an effort to clean up the industry, Beijing has issued a stream of curbs on advertising of medical products and services.

The latest rule, issued in February, banned actors from playing medical experts in advertisements for drugs after a group of Internet vigilantes exposed several fake experts.

Like many regulations in China, the rules have not been strictly enforced.

“There are still these TV adverts that go on for half an hour with people saying how they are completely cured after taking a certain drug or injection,” said activist Qing Song, a hepatitis B carrier. “But these are completely wrong.”

One Chinese company promoted its anti-impotence drug by pretending that soccer star David Beckham endorsed the product even though his name and image were used without his consent.

In the advert, which featured footage of Beckham playing football, a voice speaking Mandarin, purporting to be that of the English soccer player, extolled the virtues of the drug.

“Want to know how I can keep being strong and running on the field?” said the voice-over. “USA Selikon capsules give me a big help. It is also the secret weapon with which I satisfy Victoria,” it said, referring to Beckham’s celebrity wife.

Chinese law makes it difficult for international celebrities such as Beckham to sue firms that use their likeness without their consent.

To illustrate the extent of the touting of fake drugs, one leading Chinese search engine lost 2.1 percent of its online marketing ad revenue when the government issued one of its rules limiting advertising unlicensed drugs.

Still, despite bans, unlicenced and untested medical products are heavily promoted on the Internet, TV and billboards, as well as in newspapers and magazines across China.

Another problem is drug piracy. Sometimes fake drugs are packaged and sold to look like the medications of reputable firms.

In one case in January, the government ordered doctors to stop prescribing a well-known diabetes drug after a fake batch of the medicine was linked to the deaths of two patients in the far western region of Xinjiang.

With many Chinese lacking comprehensive medical coverage and opting to self-treat rather than visit doctors, experts say that tighter regulation and better enforcement are crucial to weed out disreputable firms. At risk is the health of tens of millions of people that purchase these medications across China.

“Unlike tainted food which we can avoid, people have to take pills even after hearing so much negative news about drug quality,” complained Pang as he exited a drug store.

(Additional report by Cheong Kah Shin; Editing by Doug Young and Megan Goldin)

Glaxo and Pfizer come together to create new company, devoted to development and marketing of HIV drugs

World’s two biggest drug companies GlaxoSmithKline PLC and Pfizer Inc. will join hands to create a new company exclusively for developing and selling of HIV medicines. Both companies made announcement of the new venture on Thursday. The name of the company will be announced after the finalization of the deal. The new company will be based in London.

Glaxo Chief Executive Andrew Witty said: “The combination of a broad current revenue base and a new diverse pool of pipeline assets provides a significant platform to invest in developing and delivering new HIV medicines.”

Witty said he expects $90 million, or 60 million pounds, in savings – mostly coming next year – from cutting administration and marketing overlaps. Research and development operations would be basically unchanged.

Glaxo will have 85 percent and Pfizer have 15 percent share by revenue. Initially Glaxo will invest about $373 million, or 250 million pounds, nearly 90 percent in the new company.

Witty added: “It’s going to have two parents out there with, I think, a very rapid decision-making mechanism to allow it to be funded for what it needs to do. It will also have the flexibility to do other deals and license in other (drugs).”

US jury rules for Monsanto in PCB pollution case

BIRMINGHAM, Ala., April 14 (Reuters) – A jury in Alabama ruled on Tuesday in favor of the old Monsanto company, now Pharmacia, in a case in which it was accused of manufacturing PCBs that caused arthritis and diabetes.

Five plaintiffs who lived in Anniston, Alabama, where the company made polychlorinated biphenyls until the 1970s and had been dumping chemicals into local creeks, brought individual lawsuits against Monsanto at a state court.

The five are all senior citizens who suffer from arthritis or diabetes. They are the first of around 3,000 individuals filing lawsuits, according to plaintiff attorney Frank Davis of Davis, Norris, LLC.

“This jury … ruled that the five plaintiffs in this case failed to prove their allegations that their common illnesses were caused by exposure to PCBs many years ago from an Anniston, Alabama, plant,” defense attorney Augusta Dowd said in a statement.

“The five plaintiffs are 67 to 89 years old and they have a number of well-established health factors that could explain their health condition, including obesity, diet, tobacco smoking, family history and others,” Dowd said.

“There is no credible evidence that their illnesses are linked to PCB exposure from the plant in Anniston, where PCBs have not been manufactured for more than 30 years,” the statement said.

Pharmacia, a unit of Pfizer Inc (PFE.N), is the named defendent in the case, but Monsanto has an obligation to defend the case, Dowd said.

It was not possible to obtain immediate comment from the plaintiffs.

Much of the 2-week case revolved around whether or not the PCBs actually caused diabetes and arthritis or whether they were merely associated with it.

Monsanto manufactured PCBs, classified as probable human carcinogens by the U.S. Environmental Protection Agency, at the plant for about 40 years. They were commonly used as lubricants and coolants for electrical equipment.

The U.S. government banned most uses for PCBs in 1979. (Reporting by Peggy Gargis; Writing by Matthew Bigg; Editing by Richard Chang)

Pfizer offers to boost stake in Indian arm

NEW YORK, April 12 (Reuters) – U.S. drug maker Pfizer Inc (PFE.N) offered on Sunday to pay about $136 million to boost its stake in its Indian arm Pfizer Ltd (PFIZ.BO) to 75 percent.

Pfizer — which announced plans to buy rival Wyeth (WYE.N) for $68 billion earlier this year — said it will launch a tender offer to buy a 33.77 percent stake in the Indian business at a price of 675 rupees per share.

The offer represents a premium of more than 8 percent to the April 9 closing price for Pfizer Ltd.

Pfizer already owns 41.23 percent of the Indian company. It expects the offer, which is subject to regulatory approvals, to open in June. (Reporting by Michael Erman; Editing by Muralikumar Anantharaman)

Pfizer to make tender offer to increase stake in Pfizer Limited

Mumbai, Apr 13 (ANI/Business Wire India): Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, today announced that it will make a tender offer to acquire a 33.77 per cent stake in Pfizer Limited from public shareholders at a price of Rs. 675.00 per share.

Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75 per cent from the current level of 41.23 per cent. The offer will represent a total value of up to Rs. 6.8 billion, or approximately USD 136 million.

A public announcement will be issued in India as required by the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 (“SEBI Regulations, 1997″).

The offer for these shares, which are traded on the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE), is expected to open in June 2009 and is subject to regulatory approvals.

The open offer will be managed by HSBC Securities and Capital Markets (India) Private Limited.

The offer will be made at a premium of 8.6 per cent to the closing share price of Rs. 621.55 of Pfizer Limited on April 9, 2009, on the NSE (equivalent premium of 8.3 per cent to the closing price of Rs. 623.00 on the BSE), which was the last trading day before the announcement of the tender offer.

It will also represent a premium of 22.2 per cent over Pfizer Limited’s average share price during the 30 days ending April 9, 2009, on the NSE (equivalent premium of 22.3 per cent over the average share price during the 30 days ending April 9, 2009, on the BSE) and a premium of 45.2 per cent over the requisite price determined in accordance with SEBI Regulations, 1997. (ANI)

Sutent no better than Xeloda in treating breast cancer

Sutent no better than Xeloda in treating breast cancer Pfizer Inc (PFE. N) stopped a late-stage study of its drug Sutent. This study was evaluating effect of this drug on advanced breast cancer patients. Sutent is presently approved to treat kidney cancer and a type of gastrointestinal cancer. Company officials notified that three other Phase III trials and two mid-stage trials of Sutent are under way in advanced forms of the cancer.

Researchers were analyzing whether patients taking Sutent could survive longer than patients receiving Xeloda.

Pfizer said the Phase III trial was stopped because Sutent didn’t work better in patients than the chemotherapy drug capecitabine, sold under the brand name Xeloda by Roche (RHHBY).

Company spokesman Jack Cox said: “We remain fully committed to studying Sutent in advanced breast cancer.”

He added that he could not speculate why Sutent fell short in the study, but said the disappointing results are not necessarily an indication of how Sutent will fare in ongoing studies.